Psoriatic arthritis: improvement in outcomes but persistent sex difference – 5-year follow-up study of a Norwegian outpatient clinic population

References

• FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Primers 2021;7:59.
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700–12.
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Hansen IJW, Soldal DM, Sokka T. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in Southern Norway. Arthritis Res Ther 2015;17:219.
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Michelsen B, Tengesdal S, Hansen IJW, Diamantopoulos A, Kavanaugh A. Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther 2018;20:160.
   PubMed Web of Science ®Google Scholar
• Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18: 465–79.
   PubMed Web of Science ®Google Scholar
• Michelsen B, Diamantopoulos AP, Høiberg HK, Soldal DM, Kavanaugh A, Haugeberg G. Need for improvement in current treatment of psoriatic arthritis: study of an outpatient clinic population. J Rheumatol 2017;44:431–6.
   PubMed Web of Science ®Google Scholar
• Coates LC, van der Horst-Bruinsma IE, Lubrano E, Beaver S, Drane E, Ufuktepe B, et al. Sex-specific differences in patients with psoriatic arthritis: a systematic review. J Rheumatol 2023;50:488–96
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
   PubMed Web of Science ®Google Scholar
• Fredriksson T. Severe psoriasis – oral therapy with a new retinoid. Dermatology 1978;157:238–44.
   Web of Science ®Google Scholar
• Heuft-Dorenbosch L. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.
   PubMed Web of Science ®Google Scholar
• Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686–91.
   PubMed Web of Science ®Google Scholar
• Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2015;75:811–8.
   PubMed Web of Science ®Google Scholar
• Wells G, Becker J-C, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2008;68: 954–60.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100–S8.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965–9.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, Lhd VT, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int 2014;2014:1–12.
   Web of Science ®Google Scholar
• Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2017;77:3–17.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Coates LC. Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum 2018;47:786–96.
   PubMed Web of Science ®Google Scholar
• Rsg G, de Almeida Martins LM, de Ataide Mariz H, Dantas AT, Duarte ALBP. DAPSA versus cDAPSA: do we need to use CRP? Ann Rheum Dis 2019;79:e142–e2.
   PubMed Web of Science ®Google Scholar
• Schneeberger EE, Citera G, Nash P, Smolen JS, Mease PJ, Soriano ER, et al. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: a post hoc analysis of data from phase 3 tofacitinib studies. Semin Arthritis Rheum 2023;58:152134.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2013;73:6–16.
   PubMed Web of Science ®Google Scholar
• Colombo D, Frassi M, Pagano Mariano G, Fusaro E, Lomater C, Del Medico P, et al. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an observational longitudinal study of real-life clinical practice) observational longitudinal study. BMC Rheumatol 2022;6:57.
   PubMedGoogle Scholar
• De Vlam K, Steinfeld S, Toukap AN, van den Bosch F, Joos R, Geysens P, et al. The burden of psoriatic arthritis in the biologics era: data from the Belgian epidemiological psoriatic arthritis study. Rheumatology (Oxford) 2021;60:5677–85.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020;395:1496–505.
   PubMed Web of Science ®Google Scholar
• Eder L, Tony H-P, Odhav S, Agirregoikoa EG, Korkosz M, Schwartzman S, et al. Responses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials. Rheumatol Ther 2022;9:919–33.
   PubMed Web of Science ®Google Scholar
• Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann Rheum Dis 2022;82:496–506.
   PubMed Web of Science ®Google Scholar
• Brkic A, Diamantopoulos AP, Haavardsholm EA, Fevang BTS, Brekke LK, Loli L, et al. Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs. BMC Health Serv Res 2022;22:48.
   PubMed Web of Science ®Google Scholar
• Mourad A, Gniadecki R. Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis. J Rheumatol 2020;47:59–65.
   PubMed Web of Science ®Google Scholar
• Wu D, Yue J, Tam L-S. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford) 2017;57:563–71.
   Web of Science ®Google Scholar
• Chimenti MS, D’Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, et al. An update for the clinician on biologics for the treatment of psoriatic arthritis. Biologics 2020;14:53–75.
   PubMed Web of Science ®Google Scholar
• Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PloS One 2013;8:e63619.
   PubMed Web of Science ®Google Scholar
• Passia E, Vis M, Coates LC, Soni A, Tchetverikov I, Gerards AH, et al. Sex-specific differences and how to handle them in early psoriatic arthritis. Arthritis Res Ther 2022;24:22.
   PubMed Web of Science ®Google Scholar
• Coates LC, Strand V, Wilson H, Revicki D, Stolshek B, Samad A, et al. Measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open 2019;5:e001002.
   PubMed Web of Science ®Google Scholar
• Coates LC, Nash P, Kvien TK, Gossec L, Mease PJ, Rasouliyan L, et al. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Semin Arthritis Rheum 2020;50:709–18.
   PubMed Web of Science ®Google Scholar
• Dures E, Shepperd S, Mukherjee S, Robson J, Vlaev I, Walsh N, et al. Treat-to-target in PsA: methods and necessity. RMD Open 2020;6:e001083.
   PubMed Web of Science ®Google Scholar
• Brkic A, Łosińska K, Pripp AH, Korkosz M, Haugeberg G. Remission or not remission, that’s the question: shedding light on remission and the impact of objective and subjective measures reflecting disease activity in rheumatoid arthritis. Rheumatol Ther 2022;9:1531–47.
   PubMed Web of Science ®Google Scholar
• Hagège B, Tan E, Gayraud M, Fautrel B, Gossec L, Mitrovic S. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. Rheumatology (Oxford) 2020;59:1818–25.
   PubMed Web of Science ®Google Scholar
• Gezer HH, Duruöz MT, Nas K, Kılıç E, Sargın B, Kasman SA, et al. Inconsistencies of the disease activity assessment tools for psoriatic arthritis: challenges to rheumatologists. Joint Bone Spine 2022;89:105296.
   PubMed Web of Science ®Google Scholar
• Sorge RE, Totsch SK. Sex differences in pain. J Neurosci Res 2016;95:1271–81.
   PubMed Web of Science ®Google Scholar
• Colombo D, Frassi M, Mariano GP, Fusaro E, Lomater C, Medico PD, et al. The CHRONOS real-world evidence of biologic treatments in psoriatic arthritis in Italy: a post hoc gender analysis. Womens Health Rep (New Rochelle) 2022;3:162–71.
   PubMedGoogle Scholar
• Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 2007;66:1221–6.
   PubMed Web of Science ®Google Scholar
• Hamann PDH, Shaddick G, Hyrich K, Green A, McHugh N, Pauling JD. Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis. Rheumatology (Oxford) 2018;58:831–5.
   Web of Science ®Google Scholar
• Højgaard P, Ballegaard C, Cordtz R, Zobbe K, Clausen M, Glintborg B, et al. Gender differences in biologic treatment outcomes – a study of 1750 patients with psoriatic arthritis using Danish health care registers. Rheumatology (Oxford) 2018;57:1651–60.
   PubMed Web of Science ®Google Scholar
• Duruöz MT, Gezer HH, Nas K, Kılıç E, Sargın B, Kasman SA, et al. Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: a multi-center study. Joint Bone Spine 2021;88:105177.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM, Scriffignano S, Coates LC, Helliwell P. Sustained very low disease activity and remission in psoriatic arthritis patients. Rheumatol Ther 2019;6:521–8.
   PubMed Web of Science ®Google Scholar
• Alharbi S, Ye JY, Lee K-A, Chandran V, Cook RJ, Gladman DD. Remission in psoriatic arthritis: definition and predictors. Semin Arthritis Rheum 2020;50:1494–9.
   PubMed Web of Science ®Google Scholar
• Kerola AM, Rollefstad S, Kazemi A, Wibetoe G, Sexton J, Mars N, et al. Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol 2023;52:42–50.
   PubMed Web of Science ®Google Scholar